Literature DB >> 12835955

Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy.

Rüdiger Becker1, Markus Haass, Dirk Ick, Carsten Krueger, Alexander Bauer, Julia C Senges-Becker, Frederik Voss, Thomas Hilbel, Feraydoon Niroomand, Hugo A Katus, Wolfgang Schoels.   

Abstract

BACKGROUND: The prognostic role of asymptomatic nonsustained ventricular tachycardia (NSVT) and programmed ventricular stimulation (PVS) in patients with idiopathic dilated cardiomyopathy (IDC) remains controversial.
METHODS: The prognostic significance of ventricular arrhythmias, ejection fraction, NYHA class, atrial fibrillation and age for overall and sudden death mortality was prospectively studied in 157 patients with IDC (group 1) free of documented sustained ventricular arrhythmia and syncope. In 99 patients with asymptomatic NSVT (group 2), PVS with 2 - 3 extrastimuli was performed. Non-inducible patients were discharged without specific antiarrhythmic therapy, whereas those with inducible monomorphic ventricular tachycardia were implanted with an ICD.
RESULTS: In group 1, 48% of patients had NSVT. Overall and sudden death mortality were significantly higher in patients with NSVT (34.2 vs. 9.8%, p = 0.0001 and 15.8 vs. 3.7%, p = 0.0037; follow-up 22 +/- 14 months). Multivariate analysis revealed that NSVT independently predicts both overall and sudden death mortality (p = 0.0021 and.0221, respectively; adjusted for EF, NYHA class and age). In group 2, inducibility of sustained ventricular tachyarrhythmia was 7%, but sustained monomorphic VT occurred in 3% only. Two of 7 inducible patients experienced arrhythmic events during a follow-up of 25 +/- 21 months (positive predictive value 29%). Overall and sudden death mortality were 29% and 0% in the inducible group vs. 17 and 4% in the non-inducible group. Both overall and sudden death mortality were significantly lower in non-inducible patients from group 2 as compared to patients from group 1 with NSVT (p = 0.0043 and 0.0048), most likely due to a more common use of betablockers and a higher EF in the former group (p < 0.001, respectively).
CONCLUSIONS: In patients with IDC, NSVT independently predicts both overall and sudden death mortality. Due to a low inducibility rate and a poor positive predictive value, PVS seems inappropriate for further arrhythmia risk assessment. However, in spite of documented NSVT, the incidence of SCD in patients on optimized medical treatment including betablockers seems to be very low, questioning the need for specific arrhythmia risk stratification.

Entities:  

Mesh:

Year:  2003        PMID: 12835955     DOI: 10.1007/s00395-003-0398-7

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  4 in total

1.  Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls.

Authors:  Thomas Pezawas; André Diedrich; Robert Winker; David Robertson; Bernhard Richter; Li Wang; Daniel W Byrne; Herwig Schmidinger
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-09-27

2.  Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events.

Authors:  Tobias Simon; Ruediger Becker; Frederik Voss; Olympia Bikou; Melanie Hauck; Manuela Licka; Hugo A Katus; Alexander Bauer
Journal:  Clin Res Cardiol       Date:  2008-01-14       Impact factor: 5.460

3.  Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients.

Authors:  F Picard; M Brehm; M Fassbach; B Pelzer; S Scheuring; P Küry; B E Strauer; B Schwartzkopff
Journal:  Clin Res Cardiol       Date:  2006-04-03       Impact factor: 6.138

4.  Risk stratification for sudden cardiac death in patients with non-ischemic dilated cardiomyopathy.

Authors:  Karthik Shekha; Joydeep Ghosh; Deepak Thekkoott; Yisachar Greenberg
Journal:  Indian Pacing Electrophysiol J       Date:  2005-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.